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Bayesian association scan reveals loci associated
with human lifespan and linked biomarkers
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The enormous variation in human lifespan is in part due to a myriad of sequence variants,
only a few of which have been revealed to date. Since many life-shortening events are related
to diseases, we developed a Mendelian randomization-based method combining 58 disease-
related GWA studies to derive longevity priors for all HapMap SNPs. A Bayesian association
scan, informed by these priors, for parental age of death in the UK Biobank study
(n¼ 116,279) revealed 16 independent SNPs with signiﬁcant Bayes factor at a 5% false
discovery rate (FDR). Eleven of them replicate (5% FDR) in ﬁve independent longevity
studies combined; all but three are depleted of the life-shortening alleles in older Biobank
participants. Further analysis revealed that brain expression levels of nearby genes (RBM6,
SULT1A1 and CHRNA5) might be causally implicated in longevity. Gene expression and caloric
restriction experiments in model organisms conﬁrm the conserved role for RBM6 and SULT1A1
in modulating lifespan.
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H
uman lifespan is a highly variable and heterogeneous
trait1. Until the 19th century average life expectancy was
B30–40 years2. The sharp rise in life expectancy over the
past century is due primarily to improved housing, nutrition,
hygiene and vaccines3, which greatly enhanced the chances to
survive childhood and young adulthood4.
While most determinants of life expectancy are still
environmental (for example, socio-economic status, smoking
and other lifestyle factors and gender1), numerous twin studies5
suggest that in modern societies 20–30% of human lifespan
variation is due to genetic factors, perhaps up to 40% when
looking at survival beyond 85–100 years, often termed
longevity1,6,7. Longer lifespan is strongly associated with later
disease onset and as such is likely inﬂuenced by many genetic
variants via predisposition to, or protection from certain
diseases5, or their risk factors.
Genome-wide association studies (GWAS) have been
instrumental in revealing disease susceptibility8 and longevity-
associated loci. However, these studies have so far revealed only a
handful of robustly replicating genetic variants. Most studies have
focussed on an extreme case–control design, where ‘cases’ were
deﬁned as individuals surviving past 90 years of age and controls
were those who died at earlier ages, typically before 80. The
bottleneck in these studies is the availability of genotyped samples
from nonagenarians, however, increasing sample sizes from
n¼ 1,836 (ref. 9; at which no variants were signiﬁcant) to
n¼ 6,036 (ref. 10) and n¼ 7,729 (ref. 11), revealed ﬁrst the
TOMM40/APOE/APOC1 (rs4420638) and FOXO3 (rs10457180)
loci, although not at genome-wide signiﬁcance level. A meta-
analysis of European longevity cohorts conﬁrmed APOE
(rs4420638, Po3.4 10 36) and revealed a new locus near
EBF1 (rs2149954, P¼ 1.74 10 8)11. Another approach to
identify lifespan-associated loci uses survival analysis, however
an early genome-wide study of 25,007 individuals, of whom 8,444
died during the follow-up period failed to identify any signiﬁcant
ﬁndings, or overlaps with previous studies12.
Two recent studies13,14 analysed parental longevity in the
UK Biobank15: both highlighted a disease locus, CHRNA3/5
(Po10 16), known to associate with lung cancer linked to
smoking16. Presumably due to the more powerful method, using
information from all parents, alive or dead, in a Cox-regression
framework14, both detected the well-known APOE region
(Po10 19), also associated with Alzheimer’s disease17, whilst
neither study replicated FOXO3 or EBF1. These ﬁndings suggest
disease-associated loci may serve as good candidates for
lifespan studies. Indeed, a recent GWAS on extreme longevity18
proposed a weighted hypothesis-testing approach, in which single
nucleotide polymorphisms (SNPs) are up-weighted if their
association P value combined over 14 disease-related traits is
lower. This approach enabled the discovery of three novel loci
implicated in extreme longevity.
Here we improve and extend these approaches using: (i) a
Bayesian approach to derive a meaningful prior effect size for
each SNP; (ii) estimating and accounting for all effect directions
(that is, the SNP-phenotype effect sizes and the trait-lifespan
causal effect sizes); (iii) analysing lifespan in a general population
cohort of the UK Biobank study14 rather than extreme longevity;
(iv) looking up the 16 top associations in four additional
longevity studies10–12,18; (v) performing extensive bio-
informatics follow-up and transcriptomic experiments in mice.
The key aims of our study are to (i) discover new variants
impacting mortality and doing this by developing a mechanistic
model to estimate morbidity priors for each SNP; (ii) understand
through which disease-predisposition they act; (iii) reveal the
discrepancy between the life-shortening effect of a SNP and its
effect on various life-shortening diseases; (iv) shed light on
transcriptome biomarkers that may be causally involved in this
process; (v) elucidate whether these processes are shared between
mice and human.
Results
Methods overview. We used parental lifespan-association
summary statistics (Z-statistics of the linear regression) from the
UK Biobank study14. For simplicity, in the following, we will use
the term lifespan to refer to parental lifespan.
For each SNP, we compute a novel test statistic, based on a
Bayes factor (BF). With simulations, we draw a large sample of
how these statistics would be distributed if the null hypothesis
were true for every SNP, that is, no effect of any SNP on lifespan.
This allows us to compute a P value for each observed test
statistic, comparing the observed test statistic to the large sample
of ‘null’ test statistics. In this framework, the goal is to compute a
novel test statistic which is more powerful than the conventional
lifespan Z-statistic of
bbﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
VarðbbÞq . Given two point hypotheses, the
likelihood ratio test is the most powerful test19. We use a BF as
the likelihood ratio. For each SNP, the two hypotheses of interest
are the null hypothesis of no effect on lifespan and an alternative
hypothesis, which we refer to as a prior. The prior is a prediction
of the lifespan effect size, based on the effect sizes of the same
SNP for other disease-related traits and an (out-of-sample)
estimate of the causal effect of these traits on lifespan. The steps
taken, in order, are: (1) Impute Z-statistics for all SNPs of interest
in lifespan and in other traits of interest. (2) Estimate the causal
effects of traits on lifespan using Mendelian randomization (MR).
(3) Build the prior for each SNP. (4) Compute the BFs for each
SNP. (5) Sample the ‘null’ BFs. (6) Compute P values by
comparing the observed BFs to the ‘null’ BFs. All these steps are
explained in details in the ‘Methods section’.
The ﬁrst step is performed with a standard summary statistic
imputation method20. To tackle step 2, we ﬁrst collected a large
compendium of 58 eligible association studies representing
36 distinct traits potentially impacting lifespan (Supplementary
Table 1). These association scores were subjected to multivariate,
out-of-sample MR analysis to estimate the causal effect of these
traits on parental lifespan (Methods section). In step 3, we then
deﬁned the per-trait prior effect of each SNP as the product of its
effect on a trait and the causal effect of this trait on lifespan.
These per-trait priors were summed up to yield a prior effect
estimate for each SNP on lifespan. Steps 2&3 are illustrated in
Fig. 1.
Next, the derived priors were combined with the observed
longevity association statistics to calculate the BF. The ﬁnal step
was to compare the obtained BFs to the distribution expected
under the null hypothesis, allowing us to compute empirical
P values control the false discovery rate (FDR) regardless of the
correctness of the priors. Aside from these permutation-based
P values, all P values in this paper are based on a normally
distributed test statistic and a null hypothesis of no effect of
the SNP (or trait) on lifespan. The GWAS data we used for
non-lifespan traits includes P values; from these P values and the
effect direction we inferred the Z-statistics.
Possible causal effects of GWAS traits on parental lifespan.
The instrument (SNPs) selection, a key component of any
MR analysis, depends on the association P value threshold and
strength of linkage disequilibrium (LD) pruning. We have
explored multiple settings (Supplementary Fig. 1) and, as a
compromise, chose intermediate instrument strength (Po10 5)
and moderate LD pruning (LDo0.2). The multivariate MR
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identiﬁed 11 traits with signiﬁcant causal effects on lifespan
(Table 1 and Fig. 2). Note that the estimates presented here are
multivariate, which is necessary to create priors that avoid double
counting the effect of pleiotropic SNPs. In univariate MR,
many other traits show signiﬁcant univariate causal effect
(Supplementary Table 1). The 11 traits were selected based on
Akaike Information Criterion (AIC) after removing any traits
with multivariate P value40.05. The complete model explained
7.7% of the variability of lifespan effect sizes. Most causal effect
directions were in line with the literature and mechanistic
explanations: having higher education level, higher high-density
lipoprotein (HDL)-cholesterol level and shorter stature improves
lifespan; but higher body mass index (BMI), low-density
lipoprotein (LDL)-cholesterol, triglyceride or glucose levels,
susceptibility to coronary artery disease, major depression, type 2
diabetes (T2D) or schizophrenia all shorten lifespan. Smoking
intensity (measured as number of cigarettes per day) showed a
clear negative impact on lifespan. Less intuitively, the link
between tall stature and shorter lifespan has been shown in
several studies, some explaining the link by cancer risk21.
Only one cancer study (neuroblastoma) passed our inclusion
criteria, hence due to the weakness of the available instruments
the impact of most cancers could not be investigated here. In
order to provide further evidence that these causal estimates yield
robust priors, we performed MR using instruments only from
chromosomes 1 to 6 and another MR analysis with instruments
only from chromosomes 7 to 22. Although the selected traits
did not perfectly agree (Supplementary Table 2), both the causal
effect sizes and the resulting priors were highly concordant
(Supplementary Fig. 2). In addition, we examined the MR
residuals to ensure that there was no instrument with indication
to violate the third MR assumption, that is, that the instrument
must be independent of disease-lifespan confounders. If such
violation occurs, the instrument would have a disease-
independent (pleiotropic) impact on lifespan and hence the
observed SNP-lifespan effect would deviate substantially from the
prior effect. We observed only a slight deviation for one
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Figure 1 | Analysis steps to obtain longevity prior effects for Bayesian analysis. For each SNP its prior effect on lifespan is calculated as the product
of the effect of the SNP i on GWAS traits (risk factors) ½bGi;t and the causal effect of the trait t on lifespan [b^t], summed over all available T GWAS traits.
The causal effects of the traits on lifespan were calculated via a leave-one-chromosome out multivariate Mendelian randomization.
Table 1 | Multivariate causal effect estimates for the 11 traits
chosen by the AIC-based stepwise model selection.
Trait Effect size s.e. P value
Education level 0.1810 0.0144 5.40E-36
Cholesterol LDL 0.0587 0.0050 5.90E-32
BMI 0.0958 0.0132 3.73E-13
Smoking 0.1575 0.0248 2.14E-10
Coronary artery disease 0.0934 0.0166 1.77E-08
Type 2 diabetes 0.0716 0.0158 5.9562E-06
Schizophrenia 0.0196 0.0068 0.0039
Cholesterol HDL 0.0223 0.0078 0.0041
Height 0.0131 0.0045 0.0041
Triglycerides 0.0240 0.0089 0.0071
Glucose 0.0433 0.0165 0.0086
Education level
Glucose
–0.2 –0.1 0.10.0
Standardized multivariate causal effect estimate
0.2
Cholesterol–HDL
Height
Schizophrenia
Triglycerides
Type 2 diabetes
Coronary artery disease
Smoking
Body mass index
Cholesterol–LDL
Figure 2 | Multivariate MR causal effect estimates and 95% conﬁdence
intervals of the 11 signiﬁcant traits on lifespan. Effects are standardized
such that they correspond to the square-root of the variance explained. In
other terms, for example, 1 SD increase in BMI leads to 0.09 SD reduction
in lifespan. Each black vertical bar represents the causal effect estimates
obtained when leaving one chromosome in the estimation (Methods
section).
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instrument (a SNP near APOE, rs7256200) on the residual
qq-plot for all the 22 leave-one-chromosome-out estimation
(Supplementary Fig. 3). Due to the large number of instruments,
excluding this single SNP does not change noticeably the results.
While many of the obtained causal effect estimates seem
plausible and in line with literature evidence, we do not claim that
these causal effect estimates are unbiased, neither that no
instruments violated MR assumptions. This step was necessary
only to obtain sensible priors for the downstream analysis.
If these estimates are wrong, our prior is less informative, yielding
fewer discoveries.
Computing prior effect estimates. In total 77,963 SNPs had
association P value o10 5 with at least one of the 11 traits
identiﬁed in the previous step to be causally linked to lifespan. For
each of these SNPs we calculated the product of its effect on a
given trait (set to zero if the association P value410 5) and the
estimated causal effect of the trait on lifespan. These products
were then summed up for all the 11 traits and used as prior effect
estimate of the SNP on lifespan. For illustration we show how the
effect sizes of these 78K SNPs for four important traits compare
to their effect on lifespan (Supplementary Fig. 4). Note that the
agreement is far from perfect, but when combined together into a
prior it correlates well with the estimated effect on lifespan in the
UK Biobank study (Supplementary Fig. 5). We also computed
priors for the remainder of the 2.3 million HapMap SNPs for
which we imputed lifespan-association Z-statistics and effect
estimates—their prior distribution was set to have zero mean as
none of them were signiﬁcant at 10 5 for any of the 11 traits.
Loci surviving 5% false discovery rate. Combining the priors
with the observed longevity summary statistics we obtained
BF for all 2.3 million SNPs and generated 1000 null GWAS
associations to derive null BFs. The generated 2.3 billion (1,000
permutations 2,350,352 SNPs) null BFs were used to assign
P values to each observed BF. The Manhattan plot highlights the
16 associated loci surviving 5% FDR (Fig. 3). For each locus we
selected the SNP with the largest BF, the resulting 16 SNPs are
completely independent of each other and described in Table 2.
Conditional analysis performed at each locus revealed no
secondary association signal beyond the top hit. In the QQ-plot,
the permutation-based BF P values show good adherence to the
null distribution for B99% of the selected SNPs with genomic
lambda of 1.002 (Supplementary Fig. 6). If we use only the 77,963
SNPs with prior estimate different from zero, reveals a convincing
enrichment of low lifespan-association P values (Supplementary
Fig. 7). If one wishes to control FWER, 4 SNPs (in/near LPA,
CDKN2BAS, CHRNA5 and APOE/APOC1) survive the more
stringent Bonferroni threshold (5 10 8).
Details of these top hits are shown in Table 2. Remarkably,
14 out of the 16 SNPs lie within 1 kb of a coding sequence, but
none of them are coding variants. Since these SNPs were
discovered due to their prior association with various diseases, we
also checked which diseases these SNPs are already known to be
associated with. Most of these SNPs (or their LD-proxies) have
been previously associated with clinically important traits, most
frequently: LDL-, triglyceride-, total cholesterol-, education levels,
BMI, height and coronary artery disease (Table 2). Interestingly,
an intronic SNP of the BMI-associated FTO gene also features in
the list of 16 top hits. However, three of them (rs2909448 in
DPP4, rs362296 in MSANTD1, rs729583 in SNX29) have not yet
been associated with any trait at genome-wide signiﬁcant level.
In Table 2 we also report the hazard ratio (HR) for survival
beyond age 40 per allelic dosage in offspring for the 16 top hits.
The HR was calculated directly in UK Biobank for the genetically
British with valid mother/father survival information and
maternal and paternal effects were combined. Using only dead
parents we also estimated the effect of these SNPs in term of years
of life lost per allele. For example, the strongest APOE/APOC1
(rs4420638) variant has HR¼ 1.038 and each copy of the G allele
decreases life by B5 months.
Lookup of the 16 loci in other longevity studies. Given the large
sample size of the UK Biobank compared to other previous
independent studies we ﬁrst assessed power to replicate our
ﬁndings in the combined CHARGE studies. First, we performed
power calculations assuming a replication study with 14,000
samples selected from the top and bottom 5% tail of a general
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Figure 3 | Manhattan plot of the permutation P values of the BF. The nearest genes to the 16 signiﬁcant loci are indicated next to the lead SNP. Regions
implicated in a recent longevity study18 are highlighted in green. X-axis represents the chromosome number and the physical position within each
chromosome.
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lifespan distribution and a SNP explaining B1% of lifespan
variability. These calculations showed that apart from the top two
hits (APOE and CHRNA3/5) we have only 16% (for the FTO
variant) to 73% (for the SNP near BSND) power to replicate our
ﬁndings with a P value below 0.05/16 in a study very similar to
the combined CHARGE data set. For this reason we call our
analysis as a lookup, given that strict replication is impossible due
to power considerations.
The 16 signiﬁcant SNPs were tested against summary statistics
from all available replication studies: the CHARGE study10 , the
EU longevity11, a genome-wide survival study12 and a recent
disease-informed extreme longevity GWAS18 including two
cohorts. We combined evidence at the P value level and meta-
analysed P values using the Fisher’s method22 while accounting
for study overlap (Methods section). Notably, 11 of the 16 SNPs
can be declared signiﬁcant based on its combined replication
P value at 5% FDR (Table 2 and Supplementary Table 3).
Some of these 16 SNPs (near APOE/APOC1, LPA and FTO)
seemed to have larger effects on extreme longevity
(Supplementary Fig. 8). There are several explanations for this:
(i) Markers related to late onset diseases (such as Alzheimer’s) are
bound to be less pronounced effect earlier. (ii) Inﬂated extreme
longevity effects can also be put down to the fact that testing the
extremes of a distribution versus the whole distribution by
deﬁnition yields larger effects. (iii) Moreover, the UK Biobank
study used offspring genotypes as proxy for parental genotypes,
which results in estimates biased towards zero. On the other
hand, we also observe a handful of SNPs (for example, in
CHRNA5, LPL) impacting lifespan only in the normal range, but
with negligible effect on extreme lifespan.
In summary, 12 out of the 16 hits replicate in at least one of the
replication studies with nominal signiﬁcant one-sided P value and
9 of these (in/near BSND, CELSR2, FTH1P5, LPA, CDKN2BAS,
CHRNA5, NPIPB8, FTO and APOE/APOC1) survive Bonferroni
correction (0.05/16).
Finally, we veriﬁed that 13 out of the 16 life-shortening
alleles are depleted in older study participants of the UK
Biobank (P¼ 0.0021) and ﬁve of them have nominally
signiﬁcant association with participant age (P¼ 8.09 10 5).
This observation is concordant with the selection bias of study
participants: those that are able to make it to population cohort
studies are in better health than the overall population. Hence,
people carrying life-shortening (or disease-associated) alleles are
less likely to make it to a cohort at an older age resulting in lower
life-shortening allele frequency as a function of participant age in
the UK Biobank (Fig. 4).
Replication of previous associations. As expected, the well-
established APOE locus is convincingly conﬁrmed in our study,
being the top associated locus. The lifespan-shortening FOXO3
variant (rs10457180-A) did not replicate in our study (P¼ 0.41).
The longevity-associated EBF1 variant (rs2149954-T) found in
the largest European GWAS11 in the UK Biobank analysis did not
reach nominal signiﬁcance (imputed P value¼ 0.16) and was
assigned zero prior in our analysis.
A large study on the genetics of survival12 put forward 14
candidate SNPs that reached a mild cutoff of Po10 5. None of
these SNPs attained a nominally signiﬁcant P value in our study
(Supplementary Table 4), moreover the effect directions agreed
only for ﬁve out of 12 SNPs we could impute.
A recent extreme longevity study18 found four novel
associated protective alleles near CDKN2B/ANRIL (rs4977756-G),
SH2B3/ATXN2 (rs3184504-G), ABO (rs514659-A) and HLA
(rs3763305-A). Remarkably, the ﬁrst two variants replicated
in our analysis with (one-sided) P values P¼ 4.34 10 6,
P¼ 1.08 10 3, P¼ 0.03, P¼ 0.51, respectively.
Gene expression and methylation as marker for biological age.
We applied MR to test whether the expression of certain genes at
the 16 lifespan-associated loci may be causally driving lifespan.
The rationale behind MR is that if a gene expression in a given
tissue is causally related to lifespan, SNPs modulating its
expression must have an effect on lifespan proportional to the
effect on the expression. We investigated 91 gene-tissue pairs
(equivalent to 57 independent tests) at the 16 loci that had more
than ﬁve independent eQTL SNPs in a GTEx (ref. 23) tissue to be
sure that the signal is not driven by pleiotropy. Three genes
(SULT1A1, CHRNA5 and RBM6) showed signiﬁcant negative
causal effects (all in brain) on lifespan, that is, lower expression
extending lifespan (Supplementary Table 5).
If the expression of a gene correlates with chronological age, it
may be an indicator for the biological age and may be linked to
lifespan24. This hypothesis was formally conﬁrmed for age-
associated methylation levels25. If the expression of age-correlated
genes tends to modulate lifespan, SNPs regulating their
expression may inﬂuence lifespan through the altered
expression. To test this hypothesis, we explored whether SNPs
that at least mildly regulate peripheral blood expression level26
(Po10 4) of age-associated genes24 are enriched for lower than
expected longevity P values. This set of SNPs, however, showed
no signiﬁcant enrichment in low P values. Similarly, we found no
signiﬁcant enrichment of lower than expected lifespan P values
Table 2 | List of the 16 lifespan-associated SNPs at 5% FDR level.
Chr Position Rs number A1 A2 EAF Gene Category Prior s.e.
prior
UKBB
Z-stat
Log
BF
P (BF) UKBB
HR
UKBB
effect
(month)
P rep Trait GWAS
Study Z-stat Study P
1 55487346 rs12117661 G C 0.24 BSND Intergenic 0.552 0.362 4.792 3.471 5.47E-07 0.981 5.6 0.003 LDL  9.13 7.00E-20
1 56962821 rs17114036 G A 0.09 PPAP2B Intron 0.796 0.384 3.407 2.765 1.80E-06 0.978 1.8 0.325 CARDIOGRAM  5.67 1.43E-08
1 109818530 rs646776 T C 0.78 CELSR2 nearGene-3  2.921 0.436  3.119 4.761 6.97E-08 1.015  1.1 0.001 LDL 35.27 1.63E-272
2 162866255 rs2909448 T C 0.55 DPP4 Intron 0.559 0.363 3.602 2.335 4.63E-06 0.987 3.3 0.252 EDU_2016 4.86 1.20E-06
3 49890613 rs2352974 T C 0.49 TRAIP Intron 0.944 0.368  3.018 2.597 2.53E-06 1.013  3.2 0.012 EDU_2016  8.51 1.69E-17
4 3247007 rs362296 A C 0.38 MSANTD1 UTR-5 0.551 0.359 3.729 2.419 3.80E-06 0.987 4.8 0.093 EDU_2016 4.95 7.45E-07
5 55860866 rs3936510 T G 0.2 C5ORF67 Intron 0.550 0.375  3.547 2.286 5.19E-06 1.016  3.4 0.003 TG 7.73 1.09E-14
6 50921602 rs6904450 T A 0.18 FTH1P5 Intergenic 0.654 0.366 4.331 3.353 6.45E-07 1.019 6.9 0.006 BMI_2015 10.96 6.25E-28
6 161010118 rs10455872 G A 0.08 LPA Intron  1.340 0.398 4.465 5.680 1.60E-08 1.034 6.1 7E-05 TC 8.34 7.24E-17
8 19858499 rs1581675 A T 0.26 LPL Intergenic 1.145 0.455 3.749 4.123 2.11E-07 0.984 3.0 0.167 TG  27.20 7.40E-163
9 22119195 rs1333045 C T 0.51 CDKN2BAS Intron  1.430 0.495 4.155 5.540 1.77E-08 1.014  3.7 3E-05 CARDIOGRAM 11.79 4.63E-32
15 78878541 rs951266 A G 0.33 CHRNA5 Intron 0.978 0.888  6.739 13.142 4.33E-10 1.028  5.7 0.002 Smoking 12.01 3.00E-33
16 12532918 rs729583 G C 0.61 SNX29 Intron 0.503 0.362  3.726 2.289 5.15E-06 1.014  3.7 0.361 EDU_2016 4.43 9.35E-06
16 28825605 rs2008514 A G 0.41 NPIPB8 Intron  1.342 0.378  2.970 3.184 8.22E-07 1.011  1.1 0.003 BMI_2015 10.00 1.45E-23
16 53800568 rs9939973 A G 0.42 FTO Intron  2.477 0.463  2.470 2.953 1.22E-06 1.010  1.1 2E-04 BMI_2015 25.58 2.62E-144
19 45422946 rs4420638 G A 0.19 APOC1 nearGene-3  1.567 0.422  7.340 12.706 4.33E-10 1.038 4.8 o2E-06 LDL 28.49 1.51E-178
Columns represent: chromosome, position (hg19), rs number, effect allele (A1), other allele (A2), effect allele frequency (EAF), nearest gene, SNP category, prior effect size, s.e. of the prior effect,
Z-statistic in the UK Biobank study, log BF, permutation P value of the log BF, Cox-regression HR in UK Biobank, months lost/allele effect in UK Biobank, replication P value (5 studies combined), GWAS
that shows the strongest association with the SNP [CARDIOGRAM: coronary artery disease60, smoking (cigarette per day)61, LDL62, BMI_201563, EDU_201644], GWAS Z-statistic, GWAS P value.
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among SNPs that are methylation QTLs27,28 (Po10 4) for at
least one of the 353 age-associated methylation CpG sites29.
These results indicate that many of the age-correlated biomarkers
may simply change in response to aging or are driven by
mechanisms that underlie aging.
Linking expression level and lifespan in model organisms. In
this section we focus on the three genes (SULT1A1, CHRNA5 and
RBM6) that emerged as strong candidates, and analysed whether
their expression levels (in brain) could be used as an early bio-
marker for longevity. Speciﬁcally, we looked for evidence whether
their expression or the suppression thereof may be linked to
lifespan in animal models.
We compared the lifespan and the expression level of these
focal genes in prefrontal cortex at 72 days of age in 35 strains of
LXS mouse lines30. Remarkably, lower messenger RNA level of
RBM6 in prefrontal cortex at 72 days was strongly associated
with lifespan in (P¼ 4.1 10 4, Supplementary Table 6 and
Supplementary Fig. 9). The signiﬁcant correlation persisted even
after correcting for population structure through mixed effect
models31 (P¼ 1.1 10 4). The other two genes showed no
signiﬁcant association with lifespan.
Caloric restriction (CR), deﬁned as a reduction of B20–40%
of the regular caloric intake, can extend lifespan in a large range
of organisms (C. elegans32, D. melanogaster33, mice34, rhesus
monkeys35). In humans, the evidence is less direct and based on
the improvements of primary and secondary aging traits (fasting
insulin level, body temperature, metabolic rates, inﬂammation
markers and elasticity of the cardiac left ventricle)36,37. We
therefore asked whether CR in animal models induces expression
change in any of the three focal genes. Notably, SULT1A1
expression levels are up-regulated upon CR diet in mouse
(GSE11291), (Supplementary Fig. 10). No signiﬁcant difference
was found for the other genes, neither in ﬂy (GSE26726) nor in
worm (GSE27677).
Genetics of lifespan versus extreme longevity. One key question
is whether there are speciﬁc genetic factors associated with
extreme longevity10,11, but not general lifespan14. One can
imagine that some genetic factors (for example, APOEe4)
trigger diseases with very late onset (such as Alzheimer’s),
hence these markers would not impact lifespan below 70 years of
age. To check to what extent the genomic landscape of lifespan
and extreme longevity overlap, we applied LD-score regression38.
Despite these studies do not share top hits, the analysis
comparing association summary statistics genome-wide revealed
very strong genetic correlation (rG¼ 0.73, s.e.¼ 0.11) between
these two kinds of longevity measures, indicating mostly shared
genetic mechanisms.
Discussion
In this work, we present a Bayesian approach to detect novel
associations between genetic markers and lifespan. We have
demonstrated that genome-wide disease GWAS results combined
with Mendelian randomization yield very informative prior effect
estimates for lifespan association. When using non-informative
priors only two loci could be identiﬁed14, but our approach
revealed 16 loci associated with lifespan at 5% FDR. Moreover,
if we were to use the standard association P values, but reduce
multiple testing burden to only 4% of the genome that had
non-zero prior assigned, still only three of the 16 loci would have
been recovered at 5% FDR (Supplementary Table 7).
One could argue that any SNP linked to a trait causally
affecting lifespan will eventually be associated with lifespan. Our
study points far beyond this basic statement: First, we provide
effect size estimates of the identiﬁed SNPs on various scales.
Second, three of our top hits are not associated at genome-wide
signiﬁcant level with any individual disease and only two of them
are top hit for some disease. Third, most of the 16 loci exhibit
pleiotropic effects (Fig. 5): For example, the APOE/APOC1
variant (rs4420638) decreases lifespan primarily through (beyond
the well-known effect on Alzheimer predisposition) increasing
LDL levels, but surprisingly protects from type 2 diabetes. The
CHRNA3/5 SNP (rs951266) mainly impacts lifespan through
smoking and schizophrenia predisposition; the SNX29 SNP
rs729583 seems to have little impact on most of the 11 traits;
the FTO SNP rs9939973 essentially exerts its effect on BMI and its
downstream traits. Fourth, the actual effect size estimates of the
discovered SNPs are quite far from both the priors and their
individual effect on a trait (multiplied by the impact of the trait
on lifespan; Supplementary Figs 4 and 5).
Given the size of all other published longevity GWAS, we had
low power to replicate our ﬁndings. Despite this fact many of the
discovered loci replicated in independent data sets10,12,18,39.
We performed pathway enrichment analysis by PASCAL40 using
the BF permutation-based P values (Supplementary Table 8).
Only the lipoprotein metabolism pathway and lipid digestion,
mobilization and transport showed statistically signiﬁcant
enrichment (P¼ 3.1 10 6, 1.5 10 5, respectively). This is
not unexpected, as longevity seems to be extremely complex,
impacting multiple diseases and processes.
Surprisingly, the MR analysis did not yield a signiﬁcant causal
effect of alcohol consumption on lifespan, despite epidemiological
observations41. This may be a false negative result and might be
due to the fact that the GWAS on alcohol use did not reveal
strong associations, rendering the MR less powerful. The strong
link between education level and lifespan has been seen in
other studies42, but its interpretation is not straightforward.
Educational attainment may have shared genetics with socio-
economic status, which is a more plausible underlying cause. In
line with our ﬁnding, a recent study demonstrated that genetic
risk score for education level is a strong predictor of longevity42.
Furthermore, some risk factors (lipids, blood pressure, obesity
and diabetes) have shown opposite effect on lifespan when
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Figure 4 | The frequency of life-shortening alleles decreases with the
increasing age of study participants for 13 out of the 16 SNPs. Each dot
represents a SNP, with x-coordinate marking the Z-statistic in the lifespan
association study and y-coordinate the age difference per allele (in month)
with 95% conﬁdence interval. SNPs whose effect direction agrees in the
two studies are in red, others in blue. The nearest genes of the ﬁve SNPs
with age-association Po0.05 are indicated.
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focusing on longevity only beyond 85 years43, but o15% of UK
Biobank parental lifespans fell into this category, hence this
phenomenon could only mildly worsen our prior, which was
based on younger populations. Some risk factors (for example,
BMI) can have non-linear causal relationship with lifespan, which
can render our approach less powerful.
The follow-up analyses revealed several novel insights into the
genetic underpinnings of lifespan regulation. First, we found that
while genetic effects on extreme longevity are generally larger
than on general lifespan, their global genetics are largely shared
(rG¼ 0.73). Second, the squared genetic correlation between
lifespan and the (causal effect) weighted combination of 11
traits/diseases examined in this study, calculated by LD-score
regression38, is surprisingly low 5.8% (Supplementary Fig. 5),
but in line with the one 7.7% lifespan variance explained by the
11 traits in the multivariate MR model. Second, we have also seen
that 13 of the 16 lifespan-shortening alleles are rarer in older
individuals, a clear ﬁngerprint of selection bias. The small extent
of allele depletion (o1 months difference between genotype
groups) also suggests that selection bias in general population
cohorts would not strongly inﬂuence GWAS results. Third, our
in-depth eQTL MR analysis revealed three potentially causal
genes for lifespan (in brain). Finally, the similarity of the effect of
some candidate genes and their expression levels in brain on
lifespan and trends in CR in mouse indicate evolutionary
conservation.
Our approach has several weaknesses: (i) Since the UK Biobank
study is much larger than any other lifespan study ever
conducted, meaningful replication is not possible due to these
previous studies being massively underpowered for this purpose.
(ii) We cannot identify longevity-associated SNPs whose effects
are non-disease mediated or mediated by diseases whose genetic
background is largely unknown or confounded by environmental
factors. (iii) When applying MR we did not strictly verify whether
all instruments are valid as our aim was only to obtain a sensible
causal effect estimate to deﬁne the priors, rather than accurately
establishing the true causal effect size. (iv) Sample size of the
available GWASs impacts our ability to detect traits causally
affecting lifespan. This limitation precluded us from including
most cancer GWASs to build the priors. Another example is
educational attainment: when we used the recently published
study on educational attainment44 (N¼ 293,723) in our MR
analysis, it revealed a much stronger causal evidence for lifespan
than the earlier study45 (N¼ 101,069). (v) Combining our results
with expression QTL analysis does not provide deﬁnite evidence
of the causal involvement of certain transcripts in lifespan
modulation. In addition, tissues with larger sample size have
more chance to be picked up than others. For example, in case of
the lifespan-associated rs646776 at the 1p13.3 locus (near
CELSR2) we could not detect a causally implicated mediator
gene in any tissue. However, a previous study46 showed that
this variant might exert its effect on LDL cholesterol levels
through modulating the expression of SORT1 in the liver.
We conducted MR analysis to conﬁrm this gene as the best
candidate for LDL, but not for lifespan: The reason for this is that
SORT1 has a much stronger eQTL SNP in liver (rs7528419),
which is not associated with lifespan in our study. Thus unless
rs7528419 is an invalid instrument, our observation excludes
SORT1 as causal gene for lifespan, despite being a strong
candidate for LDL.
We expect that the growing number of traits subjected to
GWASs and their increasing sample size will strengthen our
approach to reveal many more longevity-associated SNPs that act
through disease modulation. Importantly, our analysis strategy is
not speciﬁc to longevity and can provide a new statistical
framework to improve the power of future GWA studies of any
disease with well-studied risk factors.
Methods
Methods overview. A BF is computed for each SNP, compared to the distribution
of BF obtained for simulated P values under the null hypothesis of no SNP affecting
lifespan. This procedure allows us to control the FDR. To compute the BF for a
SNP, we need an alternative distribution of the SNP’s effect on lifespan, alongside
the conventional null distribution of zero effect. We use a prior distribution as our
alternative distribution, as presented in Fig. 1. In the remainder of this section,
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Figure 5 | Heatmap of the standardized effects of the 16 lifespan-associated SNPs on the 11 lifespan-impacting traits and lifespan. We plotted the
standardized effects of the 16 lifespan-associated SNPs on the 11 traits altering lifespan. Trait-increasing (decreasing) effects are shown in red (blue). Most
of these SNPs show extensive pleiotropic effects.
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these steps will be described in more detail. Note that through the whole paper we
utilize only association summary statistics, that is, the Z-statistics from the
regression (coefﬁcient estimate divided by its standard error), and not actual
genetic data, except for the UK Biobank.
Longevity studies used. The primary longevity study used is based on 116,279
individuals in the UK Biobank14. In brief, the authors use the age-of-death for the
parents as measure of longevity. Since not all parents were dead in the study, they
calculated the Martingale residuals from a Cox regression to place alive and dead
subjects (estimated) age-of-death on the same scale, thus incorporating useful
additional information over and above considering the dead alone, especially for
long-lived alive parents. Only those identiﬁed by UK Biobank15 as unambiguously
genetically British, with valid parent lifespan details and covariates were analysed.
Covariates ﬁtted in the model were subjects’ (not parental) sex, indicators of
assessment center and genotyping batch, as well as the ﬁrst 15 principal
components of the relationship matrix, as provided by the UK Biobank. One
GWAS was run for paternal and one for maternal age-of-death. These UK Biobank
analyses can be interpreted as a study on the parent’s longevity, where we use the
child’s genome as a proxy for the parent’s genome, akin to imputation. In our study
we used the combined association results for both parents via inverse-variance
weighted ﬁxed effect meta-analysis adjusted for correlated test statistics47. The
correlation between the maternal and paternal lifespan effect sizes was observed to
be 0.11 under the null.
As replication we combined two (almost) independent studies performed
by the CHARGE Consortium10 and the EU Longevity Study11. Each study is a
case–control analysis, comparing a set of cases that survived to at least 90 years of
age to a set of (differently deﬁned) younger controls. We meta-analysed these two
studies, via inverse-variance weighted ﬁxed effect meta-analysis adjusted for
correlated test statistics47 due to the fact that there are a small number of
individuals that are in both studies, to construct a single GWAS. As further
replication, we also looked up association results in the Walter et al.12 study.
Disease GWASs used. To build priors for lifespan, we assembled a compendium
of meta-analytic GWASs that are not related to lifespan nor longevity. We began
with 207 studies, made up of three groups (Supplementary Table 1). The largest
group is 144 studies that were publicly available on the dbGaP ftp site for a wide
variety of traits. We considered only studies that had at least 90,000 unique SNPs
and which had suitable column names (P value, effect allele, effect size or direction)
deﬁned. The direction of the effect (±), which is sufﬁcient for our method, is
deﬁned as the sign of ‘beta’ ﬁelds (for continuous traits) or whether ‘odds ratio’
ﬁelds are greater (þ ) or less ( ) than 1 (for binary traits).
We also included the 35 publicly available studies from the Psychiatric
Genomics Consortium (PGC), and another collection of 36 studies of various
consortia: anthropometric (GIANT), lipid (GLGC), metabolic (DIAGRAM,
MAGIC), cardiovascular (CARDIOGRAM) and other traits.
Of these studies, 60 demonstrated heritability signiﬁcantly different from zero
(Po5e-4) as estimated by LD-Score regression48. Two of these studies were
discarded because of strand ambiguity yielding 58 suitable studies for our analysis.
Imputation of association summary statistics. To have summary statistics
available for the same set of SNPs we performed summary statistic imputation20.
This imputes Z-statistics (effect size/s.e.) by assuming that the correlation between
Z-statistics is the same as the correlation between the corresponding SNPs in a
suitable reference panel of genotypes. We will refer to the Z-statistic for SNP i
under disease t as wit. When we have observed Z-statistics for a set of SNPs M, we
can impute an unobserved Z-statistic, wid, based on the observed vector,
bwid ¼ E wid wMdj½  ¼ c0iMC 1MMwMd ð1Þ
where c and C record the SNP–SNP pairwise genetic correlation matrix of the
relevant population.
We computed the correlations in the UK10K database of genotypes of 3,781
British individuals. For simplicity we chose to impute 2.1 million HapMap SNPs.
We then convert all z-statistics, observed and imputed, into the standardized effect
estimates that are used in the remainder of the method; bGit  wit= ﬃﬃﬃﬃntp where nt is
the sample size in the GWAS for disease t.
MR estimation for causal effects of diseases on lifespan. This method requires,
for each SNP, an estimate of its effect on lifespan, which is independent of its
summary statistic in the parental lifespan study. We refer to this estimate as the
prior of the SNP. To compute this prior, using the estimated effects of the SNP on
non-lifespan diseases and traits, we ﬁrst need an estimate of the effect of each of
those diseases on lifespan. In this section, we describe how to compute these causal
effect estimates. As an individual SNP may affect lifespan via two different diseases,
it is better to estimate all the causal effect estimates jointly to allow for this
correlation. We refer to this joint estimation as multivariate Mendelian
randomization (multivariate MR), and we applied it to the 58 studies with
strong instruments. We established a set of SNPs that are strong instruments
(F-statistic410, which in our case was equivalent to Po10 5) for at least one of
the 58 studies.
The conventional method to estimate the causal effects of diseases on lifespan is
to use the data on each individual’s (parental) lifespan and on each individual’s
disease status. We do not have access to such detailed data, but we describe here
how we derive equivalent estimates of the causal effect by using the Z-statistic data
that is available to us, which gives us the estimates of the effect of all the SNPs on
lifespan and on the various diseases.
Given n individuals, m SNPs and d diseases deﬁne the nm matrix Z which
records the genotype of each individual, an n d matrix X which records the
disease status of each individual for the d diseases, and a vector y of length n with
the parental lifespans. Every column of X, Z and y is assumed to have been
standardized to have mean zero and variance one.
Using two-stage least squares, we ﬁrst deﬁne
bX ¼ Z Z0Zð Þ 1Z0X ð2Þ
With such data, as described in equations (8–9) in Section 8.3.4 of Green et al.49,
we would estimate the causal effects via
bb ¼ bX0bX  1 bX0y ð3Þ
The summary statistic data, which we do have, takes the form of a vector c^ of
length m, reporting the estimate of the effect of each SNP on lifespan. Also, for the
disease traits, we have an m d matrix bG of the estimated effects of each SNP on
each disease,
c^ ¼ 1
n
Z0y ð4Þ
bG ¼ 1
n
Z0X ð5Þ
These estimates of the standardized effects come from the GWAS summary
statistics and were calculated assuming a linear model for the relationship between
each SNP and each trait (including lifespan). For example, each extra minor allele
will increase or decrease the log-odds of a binary trait, or linearly increase or
decrease continuous traits. We infer the standardized effect estimate of SNP i on
trait t, that is, G^it , from the observed (or imputed) Z-statistic and the sample size of
the GWAS for that trait, G^it  wit= ﬃﬃﬃﬃntp .
To compute bb, we begin by rearranging bX,
bX ¼ Z Z0Zð Þ 1Z0X
¼ Z 1
n
Z0Z
  11
n
Z0X
¼ Z C 1 bG
ð6Þ
where C ¼ 1nZ0Z is the genetic correlation matrix due to LD. We then substitute
this expression for bX into equation (3) yielding
bb ¼ G^0C 1Z0ZC 1G^  1G^0C 1Z0y
¼ G^0C 1 1
n
Z0ZC 1G^
  1
G^0C 1
1
n
Z0y
¼ G^0C 1CC 1G^
  1
G^0C 1bc
¼ G^0C 1G^
  1
G^0C 1bc
ð7Þ
This last equation gives us estimates for the causal effects in terms of quantities that
we have access to.
The covariance of this estimator, assuming homoscedastic errors, is
Var b^
h i
¼ s2 bX0bX  1¼ s^2 G^0C 1G^  1 ð8Þ
where
s^2 ¼ 1
n
y bXbb 0 y bXbb  ð9Þ
represents the variance of the outcome trait unexplained by the causal predictor,
which in reality is very close to 1. The covariance estimator for heteroscedastic
errors requires individual level data and hence not suitable for summary
statistics-based MR estimation. Note that Burgess et al.50 introduced a maximum
likelihood-based MR method using only summary statistics. Since the lifespan
study (UK Biobank) does not share samples with the disease trait studies, our
formula (equation 7) yields the same result conditional on the SNP-trait estimates
having little variance. To make sure that our method gave sensible results, we
implemented the maximum likelihood-based MR method by Burgess et al.50 and
conﬁrmed that we obtained indistinguishable solution to their likelihood function
(equation 1 in their study) maximization (see Supplementary Table 9 for the causal
estimate comparison and the between-trait correlation estimates (r in their paper)
are in Supplementary Table 10).
Instead of using every SNP, we use only those which are strong instruments,
and we use only a subset of those strong instruments that are spread further apart
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on the chromosomes in order that their genetic correlation is low. This separation
allows us to approximate C by the identity matrix I, which improves numerical
stability and simpliﬁes the equations. It gives us the expressions we estimate the
causal effects and the covariance of those estimates, where c^ and bG0 are computed
only over a subset of the SNPs. Refer to this small set of uncorrelated strong
instruments as S to select the relevant subset of rows from bG and c^.
To select S, the subset of strong instruments where there is a low level of genetic
correlation (LD) between instruments, we began with the SNP with the most
signiﬁcant P value (across all traits) and then discarded any SNP in LD (r240.2).
Repeating this pruning procedure results in 6,443 independent SNPs used for the
estimation of causal effects. To avoid weak instruments the standardized effects for
a SNP-trait pair with pt,i410 5 was set to zero. Deﬁne c^S as the effect estimate of
the S SNPs on lifespan. Deﬁne bGS as the effect estimates of the S SNPs on the
11 selected traits, where bGit has been set to zero if pito10 5, and we can then
simplify equations (7 and 8) to
b^¼ bG0S bGS  1bG0S c^S ð10Þ
Var b^
h i
¼ s^2 bG0S bGS  1 ð11Þ
This expression for estimating b^ is equivalent to using a linear regression between
c^S and bGS and using the estimated coefﬁcients as the estimates of the per-trait
causal effects. Instead of using all 58 non-lifespan traits, we used stepwise-selection,
starting with an empty set of traits and adding or removing to maximize the AIC.
Among AIC-selected variables we further removed those with multivariate
P value40.05, which resulted in 11 traits. In other words, 11 traits were identiﬁed
to have a signiﬁcant causal effect on lifespan. For the remainder of the method,
computing the prior and the BF, only these 11 traits were used. In all these
regression analyses we forced the intercept to be zero, but ﬁtting the intercept too
did not change the estimated causal effects (Supplementary Table 2).
To compute the BF for a given SNP, as described later, we require an estimate of
the causal effects for these 11 traits that is independent of the estimated lifespan
effect for that SNP, g^i . We therefore repeat the procedure for estimating the causal
effects 22 times, where each chromosome in turn has been ‘masked’. This gives us
22 vectors of causal effect estimates. When computing the prior for a SNP on a
given chromosome, we use causal effect estimates computed using only the
instruments from the other 21 chromosomes. This ‘masking’ process is to ensure
that the prior for the longevity Z-statistic of a particular SNP is completely
independent of its actual Z-statistic in the longevity study.
Building association prior for lifespan. The next step is to compute, for every
SNP genome-wide, a prior for its effect on longevity as a function of its estimated
effect on the 11 non-lifespan traits and the causal estimates of those 11 traits on
lifespan. For each SNP i, we therefore took the truncated standardized effect sizes
ðbGitÞ across the 11 lifespan-inﬂuencing traits and multiplied them by the estimated
causal effect for the corresponding traits (b^t , equation (10)). Note that only 77,963
SNPs had association P value o10 5 for at least one of the 11 traits, thus for all
other SNPs all bGit were set to zero, hence their prior effects to zero. The sum of
these products, mi ¼
Pd
t¼1 b^tbGit , is our prior belief of the standardized effect of the
SNP on lifespan. Given the independence of b^t and bGit , we estimated the variance
of the prior mi as
VarðmiÞ ¼ tr Var b^
  
tr Var bCi;  þ b^0Var bCi; b^þ bC0 i;Varðb^ÞbCi;
ð12Þ
where Var½b^ is estimated as s^2ðbG0S bGSÞ 1, as in equation 11, and VarðbGi;tÞ ¼ 1=nt .
It is interesting to note that our method is robust to misreported sample sizes as the
relevant term in the prior, the product bGtib^t , will be unchanged; a misreported
sample size for a given study will affect both factors in that product, but the errors
will cancel out and the prior will be unaffected.
Also, as mentioned earlier, most of the 2.3 million SNPs will have zero prior,
mi¼ 0, but the variance, Var(mi), will be non-zero and hence they do have a prior,
albeit very weak.
Bayes factors and their distribution under the null. A conventional GWAS will
consider how likely the observed lifespan or longevity z-statistic coming from a
standard normal distribution, N(0,1). When using standardized effect estimates,
their distribution under the null is 0; n 1l
 
, where nl is the sample size in the
longevity study. The prior In Bayesian analysis, we also consider the likelihood
under an alternative hypothesis to compare it to the likelihood under the null.
While under the null distribution the prior has zero mean and zero variance, the
prior distribution under the alternative hypothesis is N(mi,Var(mi)).
For each of the 2.3 million SNPs, we can now compare the effect estimate
observed in the longevity GWAS to the prior computed above. The BF is deﬁned as
the ratio of the likelihoods of the observed longevity effect size estimate, g^i , under
the two hypotheses. Considering the alternative hypothesis as a prior distribution
on d, which takes the place of the true mean, we use integration to compute the
marginal likelihood,
BFi ¼
R
L g^i; d;Var g^ið Þð ÞL d; mi;Var mið Þð Þdd
L g^i; 0;Var g^ið Þð Þ
ð13Þ
where L(g,m,s2) is the density of g under the corresponding Gaussian distribution
L g;m;s2
 ¼ 1ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2ps2
p e g mð Þ
2
2s2 ð14Þ
As shown elsewhere [http://www.cs.ubc.ca/Bmurphyk/Papers/bayesGauss.pdf],
the ratio of above is equivalent to
BFi ¼ L g^i;mi;Varðg^iÞþVarðmiÞð ÞL g^i; 0;Varðg^iÞð Þ
ð15Þ
To deﬁne a set of SNPs that survive 5% FDR we ﬁrst needed to assign P values to
the obtained BFs. As standard procedure with any test statistics (BF is a test
statistic), we used a permutation-based approach to calculate P values
corresponding to each BF (ref. 51). In practice, we generated BFs genome-wide for
the same 2.3 million SNPs when the lifespan Z-statistics (and the corresponding g^i)
were replaced by Z-statistics derived from GWAS scans with 1,000 random
outcomes. We then calculated the resulting BFs for each of the 1,000 null sets of
Z-statistics while keeping the same priors as before (N(mi,Var(mi)) for SNP i). In
formula, the BF for SNP i for the k-th random trait is deﬁned as
BFðkÞi ¼
Lðg^ðkÞi ; mi;Varðg^ðkÞi ÞþVarðmiÞÞ
L g^ðkÞi ; 0;Varðg^ðkÞi Þ
  ð16Þ
where g^ðkÞi ¼ 1nZ0i yðkÞ with Zi representing the standardized genotype vector for SNP
i and y(k) stands for the k-th random phenotype vector drawn from a standard
normal distribution. This gave us a large set of 2.3 billion (2.3 M 1,000) null BFs
emerging from the exact same SNP set with the same priors to compute empirical
P values for each observed BF. These P values were then subjected to
Benjamini–Hochberg step-up procedure to select the largest set that survives 5%
FDR. Using the null BFs, we also estimated the per comparison error rate52 (under
weak control) corresponding to our selection of 16 SNPs with logBF42.2857,
which yielded 4.88% concordantly with the 5% FDR control. The rationale behind
our FDR control procedure has been outlined and applied previously53, however
the estimation of the null BF distribution we proposed here is less arbitrary.
Calculating effect of the 16 SNPs on different scales. We followed the same
protocol to calculate Cox proportionate HRs54 for parent survival for the top
16 SNPs as was done by Joshi et al.14 (see summary above). Analyses here used
imputed allele dosages therefore subject counts (115,180/111,193 for mother/
father) are slightly higher than reported by Joshi et al.14, where subjects with
missing genotypes were excluded. Effects (log(HR)) on maternal and paternal
lifespan were meta-analysed using inverse-variance weighting55. We also used dead
parents only to estimate the effect of these SNPs on lifespan in years-per-allele
using linear regression. Another way to obtain effect estimates in terms of years of
life lost is to multiply the log (HR) by 10 (ref. 56). Since in our study the parental
genotypes were approximated with that of the offspring the observed effects are
expected to be half of the effect one could have obtained had parental genotypes
been used. To correct for this we multiplied the obtained per year effect by two in
both analysis. We compared these two estimates and found remarkable
concordance (Supplementary Table 11).
Combining evidence from replication studies. We used the following UK
Biobank-independent studies for replication: the CHARGE study10, the 90PLUS
longevity study11, a genome-wide survival study12 and a recent disease-informed
extreme longevity GWAS (iGWAS)18 including two cohorts (NECS and 90PLUS).
As effect sizes were available for the ﬁrst three studies, we combined the summary
statistics via the method of Lin et al.47 accounting for sample overlap, and then
converted the resulting summary statistics into one-sided P values. Since effect sizes
and directions are unknown for the iGWAS, we used the Fisher’s combined
probability test22 to meta-analyse the aggregated P values from the ﬁrst three
studies with the P values from the two iGWAS cohorts. To account for the sample
overlap we used 236,383 off-target SNPs (available or imputed in all studies) to
estimate the null cumulative density function for the sum of the  2ln(P) values,
instead of using a w2 distribution as done in the standard Fisher’s method. Note
that for the iGWAS NECS study we used the best available proxies for 14 of the 16
SNPs (r2 ranging 0.25–1, see Supplementary Table 12).
Relationship with age-related genes and methylation probes. To identify
potential causal genes at the 16 discovered loci, whose expression levels may
modulate lifespan, we applied Mendelian randomization. As described above
(equations (10 and 11)), MR can be performed using summary statistics only.
Such analysis elucidates whether the impact of SNPs on the expression level is
proportional to their effects on lifespan. We thus combined eQTL data (in all
GTEX tissues23) with the lifespan association results. To ensure instrument validity
we interrogated only those genes that had more than ﬁve independent eQTL SNPs.
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Next, we asked whether SNPs associated26 with at least one of the 1497
age-correlated24 gene expressions are enriched in lower than expected lifespan
association P values. Analogously, we also searched for SNPs associated27,28 with at
least one of the 353 age-associated CpG sites29 and compared their lifespan-
association P values to a random set of the same size. This analysis is meant to test
whether most age-associated biomarkers (expression or methylation) are causally
linked to lifespan.
Depletion of lifespan-shortening alleles in older people. If these 16 SNPs are
truly associated with lifespan, their life-shortening alleles should be depleted in
older individuals in general population cohorts, since people carrying these alleles
would have less chance to survive in the cohort at older ages due to selection bias.
We tested this hypothesis by modelling age as the outcome in a linear regression
with regressors such as SNP allele dosage, gender, 15 ancestry principal
components and batch indicator in 120,000 genetically white British participants of
the UK Biobank. We then asked what fraction of the one-sided P values fell below
0.05 and compared it to the expected number through the binomial test.
LXS mouse data. Male mice from 41 ILSXISS (LXS) recombinant inbred strains
were maintained ad libitum feeding30. Median lifespan was calculated to represent
longevity across strains. Microarray data from prefrontal cortex of LXS mice with
the average age of 72 days were generated by Dr Michael Miles, and downloaded
from GeneNetwork.org (GN Accession: GN130).
Caloric restriction gene expression data analysis. For each species, Affymetrix
raw .CEL ﬁles were downloaded from GEO database57 and preprocessed using
robust multi-array averaging (RMA) normalization58. The quality of datasets was
checked with principal component analysis (PCA) of the samples, gender and other
batches. Differential gene expression analysis between controls and CR samples
was performed using limma R package (R software 3.2)59. For multiple testing
correction, a FDRo0.1 was chosen. The normalized microarray expression values
of interested genes are shown on log2 scale.
Data availability. The disease GWAS summary statistics are publicly available and
the sources are provided in Supplementary Table 1. The resulting Bayesian asso-
ciation summary statistics can be downloaded from http://wp.unil.ch/sgg/bayesian-
lifespan-gwas/.
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